# US 2001/0044118 A1 · Immunoassay for LSD and 2-oxo-3-hydroxy-LSD

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044118 A1
- Document ID: US20010044118A1
- Status: Published application
- Kind: A1
- Application number: 09/733,534
- Filed: 2000-12-08
- Published: 2001-11-22
- Earliest claimed: 2000-04-07
- Assignees: Roche Diagnostics GmbH
- Inventors: Mitali Ghoshal; Stephen Vitone; Gerald F. Sigler; Alan J. McNally
- Web page: https://patentgrep.com/patent/US20010044118A1

## CPC

- C07D 457/06: Lysergic acid amides
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 33/946: {CNS-stimulants, e.g. cocaine, amphetamines}
- Y10S 436/815: Test for named compound or class of compounds
- Y10S 436/901: Drugs of abuse, e.g. narcotics, amphetamine
- Y10T 436/13: Tracers or tags
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides hapten derivatives useful for the preparation of antigens, antibodies and reagents for use in immunoassays for the detection of LSD and 2-oxo-3-hydroxy LSD. In the present invention, the 2-oxy LSD nucleus is derivatized out of the indole nitrogen to form an aminoalkyl derivative. The resulting haptens can then be further modified at this functionalized position for linking to appropriate immunogenic or labeling groups to provide reagents for immunoassays having substantially equal specificity for both LSD and 2-oxo-3-hydroxy-LSD.

## Claims

### Claim 1

A compound having the formula
4
wherein:
R1 and R2 are independently selected from the group consisting of H and CON(CH2CH3)2, provided that at least one of R1 and R2 is H,
R3 is H or OH,
R4 is a branched or straight chain linking group having 1-10 carbon atoms with 0-2 unsaturated bonds and 0-6 heteroatoms,
R5 is selected from the group consisting of COR6 and NHR7, wherein R6 is OH, L or LX and wherein R7 is H, L or LX, L is a linking group and X is a detector or carrier molecule bound through L.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is CON(CH2CH3)2 and R2 is H.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R3 is OH.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R5 is COR6 and R6 is OH.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R5 is NHR7 and R7 is H.

### Claim 6 (depends on 2)

The compound of claim 2, wherein R5 is NHR7 and R7 is a linking group L selected from the group consisting of
5
where Z is selected from the group consisting of COOH, SCN and N-hydroxysuccinimide ester.

### Claim 7 (depends on 2)

The compound of claim 2, wherein R5 is NHR7, R7 is LX and X is a carrier molecule selected from the group consisting of bovine thyroglobulin, keyhole limpet hemocyanin and bovine serum albumin.

### Claim 8 (depends on 2)

The compound of claim 2, wherein R5 is NHR7, R7 is LX and X is a detector molecule.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is CON(CH2CH3)2, R2 is H, R3 is OH, R4 is (CH2)3, R5 is NHR7 and R7 is a linking group L selected from the group consisting of
6
where Z is selected from the group consisting of COOH, NCS and N-hydroxysuccinimide ester.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R1 is CON(CH2CH3)2, R2 is H, R3 is OH, R4 is (CH2)3, R5 is NHR7 and R7 is a linking group L selected from the group consisting of
7
wherein X is a detector or a carrier molecule.

### Claim 11 (depends on 10)

The compound of claim 10, wherein X is a carrier molecule selected from the group consisting of bovine thyroglobulin, keyhole limpet hemocyanin and bovine serum albumin.

### Claim 12

An antibody having specificity for 2-oxo-3-hydroxy-LSD characterized by having cross-reactivity of greater than 50% for LSD.

### Claim 13

An antibody having specificity for LSD characterized by having cross-reactivity of greater than 50% for 2-oxo-3-hydroxy-LSD.

### Claim 14

An antibody having greater than 50% cross-reactivity for both LSD and 2-oxo-3-hydroxy-LSD.

### Claim 15

An antibody generated from a carrier molecule conjugate of 2-oxo-3-hydroxy-LSD characterized by having substantially equal cross-reactivity to LSD and to 2-oxo-3-hydroxy-LSD.

### Claim 16 (depends on 10)

An antibody generated from a carrier molecule conjugate of 2-oxo-3-hydroxy-LSD characterized by having substantially equal cross-reactivity to LSD and to 2-oxo-3-hydroxy-LSD, said antibody produced by immunization with a compound according to claim 10.

### Claim 17

A method for determining LSD and 2-oxo-3-hydroxy-LSD in a sample suspected of containing LSD and 2-oxo-3-hydroxy-LSD, said method comprising the steps of:
a. forming a reaction mixture comprising said sample, an antibody having substantially equal reactivity with LSD and 2-oxo-3-hydroxy-LSD, and a conjugate comprising an LSD hapten and a detectable label under conditions favorable for binding of said antibody to said LSD, said 2-oxo-3-hydroxy-LSD, and said conjugate
b. measuring the amount of said conjugate bound to said antibody by measuring the amount of said detectable label,
c. comparing the amount measured in step (b) with the amount of said label bound to said antibody when using a sample containing a predetermined amount of LSD and 2-oxo-3-hydroxy-LSD.

### Claim 18

A method for determining LSD and 2-oxo-3-hydroxy-LSD in a sample suspected of containing LSD and 2-oxo-3-hydroxy-LSD, said method comprising the steps of:
a. forming a reaction mixture comprising said sample, an antibody having substantially equal reactivity with LSD and 2-oxo-3-hydroxy-LSD, and a conjugate comprising a 2-oxo-3-hydroxy-LSD hapten and a detectable label under conditions favorable for binding of said antibody to said LSD, said 2-oxo-3-hydroxy-LSD, and said conjugate
b. measuring the amount of said conjugate bound to said antibody by measuring the amount of said detectable label,
c. comparing the amount measured in step (b) with the amount of said label bound to said antibody when using a sample containing a predetermined amount of LSD and 2-oxo-3-hydroxy-LSD.
